

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
ENGLISH ABSTRACT	v
THAI ABSTRACT	vii
LIST OF TABLES	x
LIST OF ILLUSTRATIONS	xii
LIST OF ABBREVIATIONS	xiv
INTRODUCTION	1
LITERATURE REVIEW	3
OBJECTIVES	16
MATERIALS AND METHODS	17
RESULTS	28
DISCUSSION	81
CONCLUSION	89
REFERENCES	90
APPENDIX	101
VITA	119

LIST OF TABLES

Table	Page
1. Treatment in DJW and diclofenac groups.	21
2. Research plan and treatment procedures during the study.	26
3. Effects of DJW and diclofenac in carrageenin-induced paw edema model.	30
4. Effects of DJW , prednisolone and diclofenac on granuloma formation and transudation in cotton pellet-induced granuloma model.	31
5. Effects of DJW , prednisolone and diclofenac on body weight and dry thymus weight in cotton pellet-induced granuloma model.	32
6. Effects of DJW , prednisolone and diclofenac on serum alkaline phosphatase in cotton pellet-induced granuloma model.	33
7. Effects of DJW, codeine and diclofenac in the early phase of the formalin test in mice.	34
8. Effects of DJW, codeine and diclofenac in the late phase of the formalin test in mice.	35
9. The quality control and standardization of DJW.	40
10. Demographic data of participants evaluated at the end of run-in period (week 0).	42
11. Base-line data for the major outcome assessments of participants evaluated at the end of run-in period (week 0).	43
12. The radiographic findings at entry into the study.	44
13. Percentage of the patients received previous OA treatments prior to this study.	45
14. Percentage of the patients self-rated the outcome of previous OA treatments.	46
15. Percentage of the patients used concomitant drug therapy during the study.	47
16. Mean VAS assessing pain and stiffness, Lequesne's functional index and time for climbing up the stairs in intent-to-treat patients (n = 100/group).	48
17. Mean VAS assessing pain and stiffness, Lequesne's functional index and time for climbing up the stairs in completers (n = 94/group).	49

Table	Page
18. Mean changes of VAS assessing pain and stiffness, Lequesne's functional index and time for climbing up the stairs in intent-to-treat patients (n = 100/group).	62
19. Mean changes of VAS assessing pain and stiffness, Lequesne's functional index and time for climbing up the stairs in completers (n = 94/group).	63
20. Physician's and patients' overall opinions evaluated during treatment.	76
21. Percentage of patients experienced adverse events during treatment.	79
22. Number of responders at the end of the study (week 4) and at 1 and 2 month(s) after treatment.	80

LIST OF ILLUSTRATIONS


Figure	Page
1. Flow chart of patients participating the clinical trial.	41
2. Mean VAS assessing pain during walking in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	50
3. Mean VAS assessing pain during standing in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	51
4. Mean VAS assessing pain during climbing up and down the stairs in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	52
5. Mean VAS assessing pain at night in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	53
6. Mean VAS assessing pain at rest in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	54
7. Mean VAS assessing total pain score in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	55
8. Mean VAS assessing pain during the most painful knee movement in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	56
9. Mean VAS assessing morning stiffness in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	57
10. Mean VAS assessing stiffness after rest in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	58
11. Mean VAS assessing total stiffness score in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	59
12. Mean Lequesne's functional index in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	60

Figure	Page
13. Mean time for climbing up the stairs in each treatment group evaluated at the end of run-in period (week 0) and during treatment.	61
14. Changes in VAS assessing pain during walking compared to the base-line values.	64
15. Changes in VAS assessing pain during standing compared to the base-line values.	65
16. Changes in VAS assessing pain during climbing up and down the stairs compared to the base-line values.	66
17. Changes in VAS assessing pain at night compared to the base-line values.	67
18. Changes in VAS assessing pain during resting compared to the base-line values.	68
19. Changes in VAS assessing total pain score compared to the base-line values.	69
20. Changes in VAS assessing pain during the most painful knee movement compared to the base-line values.	70
21. Changes in VAS assessing morning stiffness compared to the base-line values.	71
22. Changes in VAS assessing stiffness after rest compared to the base-line values.	72
23. Changes in VAS assessing total stiffness score compared to the base-line values.	73
24. Changes in Lequesne's functional index compared to the base-line values.	74
25. Changes in time for climbing up the stairs compared to the base-line values.	75
26. Mean VAS assessing physician's overall opinion of change in each treatment group evaluated during treatment.	77
27. Mean VAS assessing patients' overall opinion of change in each treatment group evaluated during treatment.	78

LIST OF ABBREVIATIONS

CFU	= colony forming unit
°C	= degree Celsius
COX	= cyclooxygenase
DJW	= Duhuo Jisheng Wan
ELISA	= Enzyme-Linked Immunosorbent Assay
g	= gram
h	= hour
ITT	= intent-to-treat
mg	= milligram
mg/kg	= milligram per kilogram body weight
min	= minute
ml	= milliliter
mm	= millimeter
μl	= microliter
MPN	= most probable number
NF	= not found
nm	= nanometer
NSAIDs	= nonsteroidal anti-inflammatory drugs
OA	= osteoarthritis
OMERACT	= the Outcome Measures in Rheumatoid Arthritis Clinical Trials
ppb	= part per billion
rpm	= round per minute
sec	= second
SD	= standard deviation
spp	= species

SYSADOA = symptomatic slow acting drugs in osteoarthritis
 VAS = visual analog scale
 WOMAC = the Western Ontario and McMaster Universities



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
 Copyright© by Chiang Mai University
 All rights reserved